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Background: Many studies have shown that microRNAs (miRNAs) exhibit altered expression in various
cancers and may play an important role as prognostic biomarkers. The present meta-analysis was un-
dertaken to summarize recent studies of the use of microRNA-145 (miR-145) in the assessment of
prostate cancer and to analyze the prognostic role of miR-145 for disease-free survival (DFS) outcome.
Methods: The present meta-analysis was performed by searching PubMed with the use of multiple
search strategies. Data were extracted from studies examining DFS in patients with prostate cancer who
showed lower expression of miR-145. Pooled hazard ratios of miR-145 and 95% conﬁdence intervals were
calculated. Four studies with a total of 211 patients were included in this meta-analysis.
Results: For overall DFS, the pooled hazard ratio of lower miR-145 expression in prostate cancer was
0.74 (95% conﬁdence interval: 0.23e2.34, P ¼ 0.001). Thus, lower miR-145 expression was found to
signiﬁcantly predict poorer outcomes.
Conclusions: The present ﬁndings suggest that downregulation of the expression of miR-145 might
predict poor prognosis in patients with prostate cancer.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer (PCa) is the most common malignancy and the
third leading cancer-related cause of death among men in the
Western world. A projected 233,000 new cases of PCa will be
diagnosed and ~29,480 men will die of the disease in the United
States alone in 2014. The mortality of PCa accounts for ~10% of all
cancer deaths.1 Although the 5-year survival rate of PCa is higher in
early-stage disease after treatment with surgical resection or
androgen deprivation therapy, one-third of treated PCa patients
will experience disease recurrence and will progress into
castration-resistant PCa, a more aggressive disease, leading to a
poor prognosis.2
Although prostate-speciﬁc antigen (PSA) levels have been used
as a predictor of biochemical progression, clinical progression, and
death from PCa, many potentially aggressive PCa tumors may
remain undetected in men because of normal PSA values. Accord-
ingly, a need exists to develop biomarkers that can supplement oranxi Dayi Hospital of Shanxi
ciﬁc Prostate Society, Published beven replace PSA for the diagnosis and prognostication of PCa.3
Many genes associated with p53 mutations,4e6 PTEN muta-
tions,7e9 PSCA mutations,10 and androgen receptor mutations11
have been investigated as markers of prognosis and disease pro-
gression of PCa, but the clinical use of these markers requires
further research.
MicroRNAs (miRNAs) are small noncoding RNAs with a length of
~22 nucleotides that predominantly bind to 30-untranslated regions
of target genes, leading to either translational repression or mRNA
degradation. miRNAs play important roles in various biological and
metabolic processes, including development, differentiation, signal
transduction, cell maintenance, disease, and cancer.12 Recent
studies have shown that miR-145 is a tumor-suppressive miRNA
that is downregulated in several cancer types, including bladder
cancer,13 colon cancer,14e16 breast cancer,17 and ovarian cancer.18
Furthermore, a lower level of miR-145 expression has been found
to be predictive of cancer progression. By contrast, the normal
tissues in which the cancers originate show good expression of
miR-145. Meanwhile, miR-145 was reported to be downregulated
in PCa tissues in many studies and to be associated with the
prognosis of PCa. However, the results of those studies were
inconclusive and might not be powerful enough owing to limitedy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 3 (2015) 71e7472sample sizes. In the present study, we evaluated the relationship
between miR-145 expression and disease-free survival (DFS)
outcome.
Materials and methods
Search strategy
This meta-analysis was carried out in accordance with the
guidelines of the Meta-analysis of Observational Studies in Epide-
miology Group.19 The PubMed and Medline databases were
searched for the last time in May 2014, and no lower date limit was
used. Only reviews published in English were evaluated. The
following search strategy was used: (“microRNA-145” OR “miR-
145” OR “miRNA-145”) AND (“prostate cancer” OR “prostate carci-
noma” OR “PCa”) AND (”prognosis” OR “prognosis”). Eligible
studies were included in the meta-analysis if they met the
following criteria: (1) they had to discuss patients with PCa; (2)
they had to measure miR-145 expression in tumor tissue; (3) they
had to investigate DFS outcome or the correlation between miR-
145 expression and clinical variables; and (4) the method of miR-
145 detection had to be the same. Articles were excluded on the
basis of any of the following criteria: (1) they were review articles,
letters, or laboratory articles; (2) they were not in English; (3) they
lacked key information for calculation by use of methods estab-
lished by Parmar et al,20 Tierney et al21; Williamson et al,22 and (4)
they were repeat studies that included the same author and the
same samples from the same patients as in a study already
included. Two reviewers (X.Z. and J.W.) independently evaluated
the titles and abstracts of the identiﬁed articles in duplicate. A ﬂow
diagram of the study selection process is presented in Fig. 1.
Data extraction
Eligible papers were reviewed independently by two in-
vestigators. Data were extracted from each study according to the
selection criteria mentioned above. We extracted the primary in-
formation, including multivariate analysis, KaplaneMeier survivalRecords identified through
database searching (n=29)
Additional records identified
through other sources (n=0)
Eligible study records after
duplicates removed(29)
4 studies picked for further
analysis after records
References screening:
No relevant publication
Studies included in quantitative 
synthesis (meta-analysis) (n=4)
Fig. 1. Study selection process.analysis, P values, and hazard ratios (HRs), independently. Further
data extracted from the studies included the ﬁrst author's name,
year of publication, origin of the study population, size of the study
population, tumor node metastasis (TNM) stage, method of
detecting miR-145, the PSA level, cutoff value, and duration of
follow-up. HR values < 1 were considered indicative of signiﬁcant
associations with poor outcome and HR values > 1 indicative of
signiﬁcant associations with good outcome. Disagreements were
resolved by discussion. All data were subject to consensus.
Statistical analysis
Heterogeneity was assessed by using Q statistics (P < 0.10 was
considered heterogeneous). Any signiﬁcant heterogeneity among
the studies was resolved by using the random-effects model.
Otherwise, the ﬁxed-effects model was used. The I2 statistic, which
measures the percentage of the total variation across studies that is
due to heterogeneity rather than to chance, was also assessed.23
The effect of miR-145 expression on DFS was estimated by using
forest plots. A pooled HR was calculated by using a ﬁxed-effects
model or a random-effects model as appropriate. A pooled HR <
1 indicated poor prognosis for the groups with lower miR-145
expression and was considered statistically signiﬁcant if the 95%
CI did not overlap 1. Publication bias was evaluated by using the
funnel plot and Begg's test, and P > 0.05 was considered indicative
of a lack of publication bias.24 All analyses were performed by using
STATAversion 12.0 (Stata Corporation, College Station, TX, USA). A P
value < 0.05 was considered to be statistically signiﬁcant.
Results
Study characteristics
Four studies were identiﬁed as eligible for full-text review.24e27
These eligible studies were published between 2009 and 2013. One
study evaluated patients from the United States,25 one evaluated
patients from China,26 one evaluated patients from Korea,27 and
one evaluated patients from Greece.28 These studies included a
total of 211 patients with amean number of 52.6 patients per study.
These four eligible studies were all retrospective cohort studies. The
method of miR-145 detection was all quantitative real-time poly-
merase chain reaction. miR-145 expression levels were measured
in tumor tissue. The mean length of follow-up ranged from 19.4
months to 82 months. Characteristics of the eligible studies are
summarized in Table 1.
Meta-analysis results
As shown in Table 1, all four studies reported the HR and 95% CI
directly. No heterogeneity was detected between the studies, as
indicated by evaluation of the relationship between the reduced
miR-145 level and DFS (I2¼ 0.0%, P¼ 0.721). Therefore, a pooled HR
and its 95% CI were calculated by use of a ﬁxed-effectsmodel. Forest
plots of the individual HR estimates and the results of the meta-
analysis are presented in Fig. 2. According to these results, lower
levels of miR-145 expression were signiﬁcantly predictive of poor
DFS. The pooled HR was 0.74 (95% CI: 0.23e2.34, P ¼ 0.001). Pub-
lication bias was evaluated by using funnel plots and Begg's tests.
No signiﬁcant publication biases were observed in this meta-
analysis (P ¼ 0.089; Fig. 3).
Discussion
PCa is a slow-growing malignant tumor of the male reproduc-
tive system. In most cases, PCa is inﬁltrative and tumor cells are
Table 1
Characteristics of four studies included in the present meta-analysis.a)
Author Origin of
population
Age (yr) N Stage PSA (ng/mL) Cut off Sampling Method Survival
analysis
Hazard ratios Follow-up (mo)
Qing et al26 2010 China 71.6 106 T1-T4 e DCt method tumor qRT-PCR DFS Reported 82
Kang et al27 2012 Korea 64.7 73 T2a-T3b 7.5 DCt method tumor qRT-PCR DFS Reported 19.4
Avgeris et al28 2013 Greece 65 62 T2a-T3b e 45th percentile tumor qRT-PCR DFS Reported 75
Schaefer et al25 2009 USA 63 76 T2a-T3b 6.7 Median tumor qRT-PCR DFS Reported 50
a) The studies included here are all retrospective cohort studies with different groups of patients.
DFS, disease-free survival; e, not mentioned; PSA, prostate speciﬁc antigen; qRT-PCR, quantitative real-time PCR.
Fig. 2. Forest plot of the relationship between downregulation of miRNA-145 level and disease-free survival in patients with prostate cancer. CI, conﬁdence interval; HR, hazard
ratio; miRNA, microRNA.
Fig. 3. Funnel plot of lower miRNA-145 expression and disease-free survival among
patients with prostate cancer. S. E. HR, hazard ratio; miRNA, microRNA.
Zhang and Wu / Prognostic role of microRNA-145 73scattered within the normal prostate stroma, making the tumor
content in each sample quite different. Therefore, an urgent need
exists to identify novel miRNAs as tools or markers for prediction of
aggressive PCa.
miR-145 was previously found to be downregulated in many
solid tumors comparedwith adjacent nontumor tissue, including in
PCa.29 Although miR-145 levels in PCa tissues are generally low
compared with those in nontumor tissues, the variations in miR-
145 expression are large, with a 10- to 30-fold range in tumor tis-
sues.29,30 This phenomenon suggests that expression of miR-145
within prostate tumor tissues may display a heterogeneous
pattern that can be used as a biomarker to differentiate PCa patientson the basis of tumor aggressiveness. However, the results of the
few previous studies that have explored the role of miR-145
deregulation in the prediction of PCa prognosis were inconsistent.
The study by Avgeris et al28 clearly supported the tumor-
suppressor role of miR-145 and highlighted its clinical utility in
PCa. In that study, the downregulation of miR-145 expression in
PCa was further correlated with a higher Gleason score, late-stage
and larger diameter tumors, and higher pretreatment and follow-
up serum PSA levels. These ﬁndings illustrate the central role of
miR-145 loss in disease progression and support the potential use
of miR-145 for improvement of prognostication. Chen et al26
analyzed PCa and benign prostate tissue samples and showed
signiﬁcantly decreased miR145 expression in PCa samples
(P < 0.001), particularly in those with tumor progression, and
suggested that miR-145 may play a major role in PCa prognosis. By
contrast, Kang et al27 did not observe an association between miR-
145 and clinicopathologic parameters of PCa (HR: 0.679, 95% CI:
0.215e2.143), indicating that these types of miRNA do not have
prognostic value for PCa patients. These results are paradoxically
consistent with results from previous studies. Schaefer et al25
performed miRNA proﬁling in 79 PCa tissues using quantitative
real-time polymerase chain reaction to evaluate the potential of
using miRNA as a prognostic marker. They reported that expression
of miR-96 was associated with Gleason score and biochemical tu-
mor recurrence after radical prostatectomy but that decreasedmiR-
145 expression was not signiﬁcantly associated with prognosis of
PCa (HR: 0.74, 95% CI: 0.23e2.34). Overall, the prognostic role of
miR-145 in PCa remains a puzzle.
The present meta-analysis is the ﬁrst systematic evaluation of
the relationship between the miR-145 expression level and the
prognosis of PCa. Downregulation of miR-145 expressionwas found
Prostate Int 3 (2015) 71e7474to be predictive of poor DFS among PCa patients in this meta-
analysis. The pooled HR of DFS was 0.48 (95% CI: 0.30e0.75). The
differences were found to be statistically signiﬁcant and no signif-
icant heterogeneity was observed during the meta-analysis
(I2 ¼ 0%).
The biological function of miR-145 may affect the relationship
between miR-145 expression and cancer outcome. The down-
regulation of miR-145 in different types of tumors suggests its role
in controlling cell proliferation, migration, and invasion.31 It has
been reported that the lower expression of miR-145 is due to the
methylation of the promoter region or p53 mutation of miR-145 in
PCa cell lines.32 Target gene searches have revealed that the pro-
apoptotic gene, TNFSF10, is signiﬁcantly upregulated by over-
expression ofmiR-145.30 Fuse et al33 identiﬁed thatmiR-145 can act
as a tumor suppressor through the direct control of FSCN1
expression in PCa cell lines. In addition, Hart et al34 showed that the
proto-oncogene ERG is a target of miR-145. Both downregulation of
the tumor suppressor miR-145 and upregulation of the ERG onco-
protein appear to be relevant for the development of PCa.34 Here
we show thatmiR-145, anmiRNAwhosemain rolewas shown to be
vascular smooth muscle cell maintenance35,36 and human embry-
onic stem cell differentiation,37 could be useful in the prognosti-
cation of PCa as single biomarker or in combination.
The present meta-analysis had some limitations. Firstly, only a
few studies have speciﬁcally regardedmiR-145 and the prognosis of
PCa. Secondly, the cutoff values differed in the different studies. A
consistent cutoff value needs to be determined in future studies.
Thirdly, in this meta-analysis, downregulation of miR-145 expres-
sion was found to have a prognostic role in PCa, but it was not
possible to conﬁrm miR-145 as an independent predictive factor.
Recently, researchers have suggested that a set of miRNAs might
have a stronger predictive effect than a single miRNA.38 Fourthly,
the expression of miR-145 was detected in tumor tissue samples
but not in serum or plasma. However, circulating prognostic
markers were found to be more valuable than tissue markers in
cancer patients.
In summary, the present meta-analysis showed the down-
regulation miR-145 expression levels to be closely associated with
poor prognosis in PCa patients. More multi-center clinical in-
vestigations with larger sample sizes should be conducted to
conﬁrm these ﬁndings.Conﬂicts of interest
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